Press coverage about PTC Therapeutics (NASDAQ:PTCT) has trended somewhat positive this week, according to Accern. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. PTC Therapeutics earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 46.5674749448152 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Shares of PTCT opened at $46.55 on Friday. PTC Therapeutics has a fifty-two week low of $14.56 and a fifty-two week high of $52.95. The firm has a market capitalization of $2.34 billion, a P/E ratio of -23.04 and a beta of 1.95. The company has a current ratio of 4.34, a quick ratio of 4.18 and a debt-to-equity ratio of 0.55.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.15. PTC Therapeutics had a negative net margin of 25.03% and a negative return on equity of 27.41%. The company had revenue of $68.74 million for the quarter, compared to analysts’ expectations of $69.83 million. analysts anticipate that PTC Therapeutics will post -1.48 EPS for the current year.

Several equities research analysts have recently issued reports on the stock. Credit Suisse Group lifted their price objective on shares of PTC Therapeutics from $49.00 to $53.00 and gave the company an “outperform” rating in a research report on Wednesday. ValuEngine upgraded shares of PTC Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 10th. Barclays lifted their price objective on shares of PTC Therapeutics from $40.00 to $43.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 8th. Bank of America lifted their price objective on shares of PTC Therapeutics from $27.00 to $31.00 and gave the company an “underperform” rating in a research report on Tuesday, July 31st. Finally, Citigroup reiterated a “buy” rating and set a $50.00 price objective (up previously from $35.00) on shares of PTC Therapeutics in a research report on Tuesday, July 24th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $33.43.

In related news, EVP Neil Gregory Almstead sold 20,000 shares of the business’s stock in a transaction on Tuesday, June 19th. The shares were sold at an average price of $48.31, for a total value of $966,200.00. Following the sale, the executive vice president now owns 37,154 shares in the company, valued at $1,794,909.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 7.50% of the company’s stock.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and Emflaza (deflazacort) for treating Duchenne muscular dystrophy.

See Also: How to Use the New Google Finance Tool

Insider Buying and Selling by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.